Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02110953 · ClinicalTrials.gov registry record · Phase 1
Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver
A Phase 1 study, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02110953 is a Phase 1 study that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 2 participants.
The verdict
NCT02110953, a Phase 1 study, was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of irinotecan-eluting beads in treating patients with colon or rectal cancer that has spread to the liver and does not respond to treatment with standard therapy. Irinotecan-eluting beads are tiny beads that have been loaded with irinotecan hydrochloride, a chemotherapy drug. Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing. This treatment delivers the chemotherapy directly to the tumor area inside the liver instead of to the whole body as with systemic delivery of the drug. Irinotecan-eluting beads may work better that standard chemotherapy in treating patients with colon or rectal cancer that has spread to the liver.
Interventions
- PROCEDURE hepatic artery embolization
- COMBINATION_PRODUCT irinotecan-eluting beads
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2016-01-29 |
| Est. Completion | 2017-08-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02110953
The ClinicalTrials.gov registry entry for NCT02110953 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which hepatic artery embolization is the first listed.
NCT02110953 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02110953 about?
NCT02110953 is a clinical study titled "Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver". This phase I trial studies the side effects and best dose of irinotecan-eluting beads in treating patients with colon or rectal cancer that has spread to the liver and does not respond to treatment with standard therapy. Irinotecan-eluting beads are tiny beads that have been loaded with irinotecan h...
What is the current status of trial NCT02110953?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2016-01-29. Estimated completion is 2017-08-16.
What interventions are being tested in trial NCT02110953?
The interventions under investigation include: hepatic artery embolization (PROCEDURE), irinotecan-eluting beads (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT02110953?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.